NCT07474194 Preoperative Clindamycin Vaginal Cream Versus Vaginal Cleansing With Povidone-iodine on Postoperative Infections After Cesarean Section
| NCT ID | NCT07474194 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Beni-Suef University |
| Condition | Infection Control / Methods |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-09-20 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 150 participants in total. It began in 2025-09-20 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the effects of preoperative prophylactic administration of clindamycin vaginal cream compared to preoperative vaginal cleansing using a 10% povidone-iodine solution on postpartum infectious morbidity.
Eligibility Criteria
Inclusion Criteria: * female participants with singleton pregnancies scheduled for elective cesarean sections at term, specifically between 37 and 40 weeks of gestation * free from any medical disorders. * The participants' ages ranged from 18 to 40 years * body mass index (BMI) ranged from 18 to 30 kg/m2 Exclusion Criteria: 1. Cases of urgent or emergent CS. 2. Abnormal vaginal secretion (bad smelling yellowish secretion, whitish cheesy discharge with pruritus, bloody discharge; etc…). 3. Women with medical disorders such as pre-gestational diabetes, anemia, hypertension, preeclampsia, or immunosuppressant pregnant women. 4. Women who had a skin infection adjacent to the operative site. 5. Allergy to topical povidone-iodine or clindamycin 6. Feverish patients or history of premature rupture of membranes or with placenta previa. 7. patients lost during follow-up were excluded from the final analysis.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07474194 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Infection Control / Methods. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07474194 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07474194 currently recruiting?
Yes, NCT07474194 is actively recruiting participants. Contact the research team at sara.abdalla@med.bsu.edu.eg for enrollment information.
Where is the NCT07474194 trial being conducted?
This trial is being conducted at Banī Suwayf, Egypt.
Who is sponsoring the NCT07474194 clinical trial?
NCT07474194 is sponsored by Beni-Suef University. The trial plans to enroll 150 participants.